These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 33141608)
1. Quantitative Evaluation of Retinal Vessel Density in Central Serous Chorioretinopathy after Half-dose Photodynamic Therapy. Xu F; Zhou L; Lai K; Gong Y; Li L; Lian P; Huang C; Ding X; Lu L; Jin C Curr Eye Res; 2021 Jun; 46(6):855-864. PubMed ID: 33141608 [TBL] [Abstract][Full Text] [Related]
2. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol. Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630 [TBL] [Abstract][Full Text] [Related]
3. Quantitative evaluation of damage to retinal capillaries caused by half-dose and half-time photodynamic therapy with optical coherent tomographic angiography. Xu F; Lai K; Zhou L; Huang C; Gong Y; Li L; Li C; Zhao H; Lu L; Jin C Photodiagnosis Photodyn Ther; 2021 Dec; 36():102477. PubMed ID: 34375777 [TBL] [Abstract][Full Text] [Related]
4. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Cheng CK; Chang CK; Peng CH Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374 [TBL] [Abstract][Full Text] [Related]
5. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Nicolò M; Zoli D; Musolino M; Traverso CE Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224 [TBL] [Abstract][Full Text] [Related]
6. Optical coherent tomographic angiographic pattern of the deep choroidal layer and choriocapillaris after photodynamic therapy for central serous chorioretinopathy. Chan SY; Pan CT; Wang Q; Shi XH; Jonas JB; Wei WB Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1365-1372. PubMed ID: 31037490 [TBL] [Abstract][Full Text] [Related]
8. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637 [TBL] [Abstract][Full Text] [Related]
9. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy. Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884 [TBL] [Abstract][Full Text] [Related]
10. Multimodal Imaging and Choroidal Volumetric Changes After Half-fluence PDT in Central Serous Chorioretinopathy. Munk MR; Shah R; Pappas F; Baddar D; Wong B; Jampol LM; Fawzi AA Curr Eye Res; 2016; 41(1):97-106. PubMed ID: 25612245 [TBL] [Abstract][Full Text] [Related]
11. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography]. Liu Y; Li L; Xu G; Wang W Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. Noh SR; Kang MS; Kim K; Kim ES; Yu SY Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247 [TBL] [Abstract][Full Text] [Related]
13. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Senturk F; Karacorlu M; Ozdemir H; Karacorlu SA; Uysal O Am J Ophthalmol; 2011 Feb; 151(2):303-9.e1. PubMed ID: 21168824 [TBL] [Abstract][Full Text] [Related]
14. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group. Roca JA; Wu L; Fromow-Guerra J; Rodríguez FJ; Berrocal MH; Rojas S; Lima LH; Gallego-Pinazo R; Chhablani J; Arevalo JF; Lozano-Rechy D; Serrano M Br J Ophthalmol; 2018 Dec; 102(12):1696-1700. PubMed ID: 29439089 [TBL] [Abstract][Full Text] [Related]
15. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy. Gulkas S; Sahin O Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613 [TBL] [Abstract][Full Text] [Related]
16. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes. Matušková V; Vysloužilová D; Uher M Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091 [TBL] [Abstract][Full Text] [Related]
17. Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy. van Rijssen TJ; Mohabati D; Dijkman G; Theelen T; de Jong EK; van Dijk EHC; Boon CJF PLoS One; 2018; 13(8):e0202549. PubMed ID: 30142176 [TBL] [Abstract][Full Text] [Related]
18. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289 [TBL] [Abstract][Full Text] [Related]
19. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy. Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561 [TBL] [Abstract][Full Text] [Related]
20. RESPONSE OF CHOROIDAL ABNORMALITIES TO PHOTODYNAMIC THERAPY VERSUS MICROPULSE LASER IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Place Trial Report No. 4. van Rijssen TJ; Hahn LC; van Dijk EHC; Tsonaka R; Scholz P; Breukink MB; Blanco-Garavito R; Souied EH; Keunen JEE; MacLaren RE; Querques G; Fauser S; Downes SM; Hoyng CB; Boon CJF Retina; 2021 Oct; 41(10):2122-2131. PubMed ID: 34543244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]